VOMIPRA Injection contains Ondansetron 4mg. It is used to prevent nausea and vomiting in cancer chemotherapy, radiation therapy, and surgery.
Ondansetron is a selective serotonin 5-HT3 receptor antagonist.
VOMIPRA Injection can be used in the treatment of the following conditions:
- VOMIPRA Injection can be used in the treatment of the following conditions:
- Chemotherapy induced Nausea and Vomiting (CINV).
- Treatment of Food-Protein Induced Enterocolitis Syndrome (FPIES).
Adults: 8mg of VOMIPRA Injection, slow IV injection immediately before chemotherapy. 4 mg given by slow IV injection at induction of anesthesia for PONV.
Children: Single IV dose of 0.15 mg/kg. IV dose must not exceed 8 mg. Two further intravenous doses may be given in 4 hr intervals. Max daily dose is 32 mg.
The antiemetic activity of the drug is brought about through the inhibition of 5-HT3 receptors present both centrally (medullary chemoreceptor zone) and peripherally (GI tract). This inhibition of 5-HT3 receptors in turn inhibits the visceral afferent stimulation of the vomiting center, likely indirectly at the level of the area postrema, as well as through direct inhibition of serotonin activity within the area postrema and the chemoreceptor trigger zone.